AI-assisted, human-published
01/04/2024 /Funding Events
HI-Bio Secures $95 Million in Series B Funding for Advancing Therapeutic Programs
Human Immunology Biosciences (HI-Bio™) secures $95 million in Series B funding to advance diverse programs and multiple clinical data readouts, supporting the progress of lead candidate felzartamab and the evaluation of HIB210's clinical properties.
AI-assisted, human-published
Latest headlines
-
-
-
Stay connected!
If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here
©2023 VentureCapital.com